Antibodies against phosphorylated vasp (vasodilator-stimulated the phosphoprotein), hybridoma cells for their production and their use

 

The invention relates to medicine and relates to monoclonal antibodies against VASP (vasodilator-stimulated the phosphoprotein), which bind VASP as antigen only when VASP is phosphorylated in the form hybridoma cells for their preparation and to the use of antibodies or fragments of antibodies as diagnostic and/or therapeutic agents. The advantage of the invention is the development of new approaches for the identification of endothelial dysfunction. 5 C. and 7 C.p. f-crystals, 1 table.

Description text in facsimile form (see graphic part).

Claims

1. Monoclonal antibody S, which is produced by hybridoma cell line having the registration number DSM ACC 2330, or its fragments, capable of binding vasodilator-stimulated the phosphoprotein (VASP) only when VASP phosphorylated at position serine-239 (phosphoserine-239 VASP).

2. The use of antibodies S or its fragments as defined in paragraph 1, as a diagnostic agent.

3. Application under item 2 for the qualitative or quantitative determination of phosphoserine-239 VASP in biological material.

4. Application under item 3, DG is the definition of phosphoserine-239 carried out by the method of Western blotting.

6. Application under item 3 or 4, where the definition of phosphoserine-239 is carried out using flow cytometry.

7. The use according to any one of paragraphs.2-6 for the detection of substances that affect the level of cGMP and/or camp in biological material.

8. The use according to any one of paragraphs.2-6 to determine the activity of endothelial factors in vivo.

9. The use according to any one of paragraphs.2-8 for detection of endothelial dysfunction.

10. Hybridoma cell line DSM ACC 2330, which produces monoclonal antibody S.

11. Diagnostic kit containing the antibody S or its fragment as defined in paragraph 1.

12. Diagnostic method, which includes the use of antibodies S or its fragments as defined in paragraph 1, to determine or influence the phosphorylation status of phosphoserine-239 VASP and/or VASP protein interactions in biological material.

Priority items:

07.11.1997 on PP.1-12;

26.03.1998 - according to the amendments in the claims.

 

Same patents:

The invention relates to medicine, in particular to neonatology

The invention relates to medicine, namely to clinical studies of cerebral circulation, which allow to assess the person's state of health after ischemic stroke

The invention relates to biology and medicine, to methods retentate chromatography for the separation of analytes in a sample

The invention relates to medicine, in particular to internal medicine

The invention relates to the field of medical biotechnology, in particular the activation of apoptin-induced apoptosis by different agents that cause transformation of cells in normal and/or prone to cancer cells
The invention relates to medicine, in particular to toxicology and resuscitation
The invention relates to medicine, in particular to obstetrics and gynecology
The invention relates to medicine, in particular to toxicology

The invention relates to biotechnology and is used for the preparation of recombinant human erythropoietin (EPO)

The invention relates to biotechnology and immunology, and can be used in immunohistochemical analysis to determine the localizationd

The invention relates to biotechnology, in particular the production of hybridomas

The invention relates to biotechnology and can be used to produce human erythropoietin

The invention relates to the field of immunology, in particular the production and use of monoclonal antibodies

The invention relates to biotechnology, namely the industrial production of human erythropoietin, concerns the creation of a new strain of Chinese hamster cells producing human erythropoietin, which can be used for therapeutic and research purposes in medicine and biology

The invention relates to medicine and relates to methods and compositions to enhance immune responses, mediated protein made of antibodies and cytokines, through co-injection of prostaglandin inhibitor

The invention relates to medicine and relates to humanized antibodies that recognize the verotoxin II, and producing their cell line
Up!